GPRC5D-Targeted CAR T Cells for MyelomaSham Mailankody, Eric L. Smith, Terence J. Purdon et al.|New England Journal of Medicine|2022Cited by 383
Activation of the ATR-mediated DNA Damage Response by the HIV-1 Viral Protein RMikhail Roshal, Vicente Planelles|Journal of Biological Chemistry|2003Cited by 200
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaOla Landgren, Neha Korde, Malin Hultcrantz et al.|JAMA Oncology|2021Cited by 119
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical TrialSham Mailankody, Eric L. Smith, Arnab Ghosh et al.|Blood|2018Cited by 100
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Ola Landgren, Neha Korde et al.|The Lancet Haematology|2021Cited by 95